Efficacy News and Research

RSS

FDA concludes no increased risk of cardiac events for patients treated with omeprazole and Nexium

The US Food and Drug Administration (FDA) has issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing anti-reflux surgery with either omeprazole (SOPRAN study) or NEXIUM (LOTUS study) treatment.

10 Dec 2007

Combination therapy including antibiotics may be beneficial for multiple sclerosis

A preliminary study suggests that combining a medication currently used to treat multiple sclerosis with an antibiotic may slow the progress of the disease, according to an article posted online today that will appear in the February 2008 print issue of Archives of Neurology.

10 Dec 2007

Study results from Zolinza (vorinostat) in combination with bortezomib for multiple myeloma trial

Results from two investigational Phase I trials of ZOLINZA (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma.

10 Dec 2007

Premature ejaculation drug Dapoxetine submitted for marketing in approval in Europe

Janssen-Cilag companies in Europe have submitted a Marketing Authorisation Application (MAA) for dapoxetine, a treatment for premature ejaculation (PE) in men 18-64 years of age.

10 Dec 2007

Transcranial magnetic stimulation effective treatment for major depression

For the first time in a large-scale study, transcranial magnetic stimulation has been shown to be an effective, non-drug treatment for major depression.

5 Dec 2007

Asacol treats UC symptoms of isolated proctitis

Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an effective and well-tolerated treatment for patients with all extents of ulcerative colitis (UC), including isolated proctitis.

5 Dec 2007

Honey a cheaper and more effective treatment for children's coughs than cough medicine

Experts in the United States say when it comes to children's coughs, natural honey offers a cheaper and more effective alternative to expensive over-the-counter cough medicines.

5 Dec 2007

Positive results from trial of investigational anti-epilepsy drug Brivaracetam

UCB has announced data demonstrating that anti-epileptic drug (AED) brivaracetam, with the proposed trade name Rikelta, administered as an adjunctive treatment in adults with refractory epilepsy with partial onset seizures, significantly reduced seizure frequency and had a side-effect profile comparable to placebo.

4 Dec 2007

Genetic markers for mental illness

Researchers have discovered natural genetic differences that might help predict the most effective antipsychotic drugs for particular patients with mental disorders such as schizophrenia, Parkinson's and drug addiction.

4 Dec 2007

Johns Hopkins Children's Center receives Gates funding for tuberculosis bacterium tracker

Johns Hopkins Children's Center has received a $946,000 grant from the Bill & Melinda Gates Foundation to design a system that visually tracks the behavior of the tuberculosis bacterium in the body and its response to current and new drug treatments.

4 Dec 2007

Merck Serono's Cyanokit approved in Europe

Merck Serono, a division of Merck KGaA, announced today that the European Commission has granted marketing authorization for its product Cyanokit (active substance: hydroxocobalamin) for the treatment of known or suspected cyanide poisoning in both adults and the pediatric population.

3 Dec 2007

FDA issues approvable letter for Nebivolol for the treatment of hypertension

Forest Laboratories, Inc. and Mylan Inc. announced that Mylan has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for nebivolol (proposed brand name Bystolic), a novel beta blocker under review for the treatment of hypertension.

2 Dec 2007

FDA approves Cymbalta for maintenance treatment of major depressive disorder

Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults.

2 Dec 2007

Sirtris Pharmaceuticals unveils promising, novel SIRT1 activators for treating diseases of aging

Sirtris Pharmaceuticals has announced that findings in the journal Nature demonstrate that Sirtris has developed novel drug candidates that offer a promising, new approach to treating diseases of aging, including Type 2 Diabetes, by targeting SIRT1, a gene that controls the aging process.

29 Nov 2007

Pneumococcal conjugate vaccines can improve the lives of HIV-infected children

An international team of experts has published the first comprehensive review of evidence on pneumococcal conjugate vaccination (PCV) for children with HIV infection.

29 Nov 2007

New anti-infective drug aims to fight drug-resistant bacteria at source

Deadly methicillin-resistant Staphylococcus aureus - MRSA - a bacterium that responds poorly to conventional antibiotic treatment, infects 90,000 Americans per year and causes 19,000 deaths, most in hospital settings.

29 Nov 2007

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

There are estimated to be between 50,000 -- 100,000 individuals in the U.S. diagnosed with chronic Immune Thrombocytopenic Purpura (ITP), an autoimmune disease that dramatically reduces the number of platelets in their blood -- causing bruises, nosebleeds and, sometimes, life-threatening brain hemorrhages.

29 Nov 2007

New drug, eltrombopag boosts platelets in hepatitis C patients

It's not a cure, but this may be some of the best news patients infected with the hepatitis C virus (HCV) have heard in a long time: A new drug, eltrombopag, appears to be effective in boosting low platelet counts, one of the major reasons why patients can't endure antiviral treatments.

29 Nov 2007

Researchers find evidence of mature heart cell potential in embryonic stem cells

In a new study, UC Davis researchers report the first functional evidence that heart cells derived from human embryonic stem cells exhibit one of the most critical properties of mature adult heart cells, an important biological process called excitation-contraction coupling.

27 Nov 2007

Blood-vessel blocker aids cancer-killing virus

Cancer-killing viruses are a promising therapy for incurable brain tumors, but their effectiveness has been limited in part because immune cells rapidly move in and eliminate them.

27 Nov 2007

Efficacy News and Research

FDA concludes no increased risk of cardiac events for patients treated with omeprazole and Nexium

Combination therapy including antibiotics may be beneficial for multiple sclerosis

Study results from Zolinza (vorinostat) in combination with bortezomib for multiple myeloma trial

Premature ejaculation drug Dapoxetine submitted for marketing in approval in Europe

Transcranial magnetic stimulation effective treatment for major depression

Asacol treats UC symptoms of isolated proctitis

Honey a cheaper and more effective treatment for children's coughs than cough medicine

Positive results from trial of investigational anti-epilepsy drug Brivaracetam

Genetic markers for mental illness

Johns Hopkins Children's Center receives Gates funding for tuberculosis bacterium tracker

Merck Serono's Cyanokit approved in Europe

FDA issues approvable letter for Nebivolol for the treatment of hypertension

FDA approves Cymbalta for maintenance treatment of major depressive disorder

Sirtris Pharmaceuticals unveils promising, novel SIRT1 activators for treating diseases of aging

Pneumococcal conjugate vaccines can improve the lives of HIV-infected children

New anti-infective drug aims to fight drug-resistant bacteria at source

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

New drug, eltrombopag boosts platelets in hepatitis C patients

Researchers find evidence of mature heart cell potential in embryonic stem cells

Blood-vessel blocker aids cancer-killing virus

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News